Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment.
Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions.
Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions.
Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
Location: China, Jiangsu, Nantong
Employees: 1001-5000
Founded date: 1998
Investors 2
| Date | Name | Website |
| - | Qiming Ven... | qimingvent... |
| - | Qiming Ven... | qimingvc.c... |
Mentions in press and media 18
| Date | Title | Description |
| 30.11.2025 | Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Aid Fund for Post-Fire Recovery | SHANGHAI, Nov. 30, 2025 /PRNewswire/ -- On the afternoon of November 26, a major Grade 5 fire spread across multiple residential buildings in Wang Fuk Court in Tai Po, Hong Kong, causing severe casualties and drawing widespread public conce... |
| 30.06.2025 | Qiming Venture Partners' Portfolio Company Unisound Successfully Lists on the Hong Kong Stock Exchange | SHANGHAI, June 30, 2025 /PRNewswire/ -- On June 30th, Beijing time, Unisound, a pioneer in the industrialization of AI technologies in China and a portfolio company of Qiming Venture Partners, has successfully debuted on the Hong Kong Stock... |
| 21.06.2025 | Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions | In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c redu... |
| 10.03.2025 | Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity | BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bof... |
| 18.12.2024 | Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase... | BEIJING and BRIDGEWATER, N.J., Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (" FDA ") has cleared the... |
| 26.11.2024 | Shifting Sands: The Evolution of Investment Strategies in a Global Landscape | In the world of finance, change is the only constant. Recently, two stories emerged that highlight this truth. One is the leadership transition at Qiming Venture Partners, a major player in Chinese venture capital. The other is the growing ... |
| 25.11.2024 | Chinese VC firm Qiming Venture Partners prepares for leadership change | After months of speculation, leadership changes at Qiming Venture Partners have been confirmed. Nisa Leung, a managing partner with 18 years at the firm, is stepping down, according to ChinaVenture. This move aligns with Qiming’s “ten-year ... |
| 13.11.2024 | Gan & Lee Pharmaceuticals: A New Era in Obesity Treatment with GZR18 | In the realm of obesity treatment, Gan & Lee Pharmaceuticals is making waves. Their recent clinical trials for GZR18, a glucagon-like peptide-1 (GLP-1) receptor agonist, are promising. The results are a beacon of hope for many strugglin... |
| 12.11.2024 | Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks | After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. The pharmacokinetic profile supports a once-daily oral dosing regimen for GZ... |
| 11.11.2024 | ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults | Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and... |
Show more